11.71

2.99% 0.34

After Hours: 11.71

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $11.71, with a volume of 1.37M. It is up +2.99% in the last 24 hours and down -25.13% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$11.37

Open:

$11.43

24h Volume:

1.37M

Relative Volume:

1.01

Market Cap:

$474.34M

Revenue:

Net Income/Loss:

$-168.05M

P/E Ratio:

-2.2827

EPS:

-5.13

Net Cash Flow:

$-146.15M

1W Performance:

-2.58%

1M Performance:

-25.13%

6M Performance:

-77.20%

1Y Performance:

-79.22%

1-Day Range:

$11.43

$11.99

1-Week Range:

$11.04

$12.56

52-Week Range:

$9.775

$73.00

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1174)

Industry

Biotechnology (678)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

160

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	11.71	474.34M	0	-168.05M	-146.15M	-5.13
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

08:34 AM

Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks

08:34 AM

08:09 AM

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times

08:09 AM

08:00 AM

Exclusive: Keros CEO Reveals Next Steps in TGF-ß Innovation at Guggenheim Conference - StockTitan

08:00 AM

Jan 29, 2025

Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? - MSN

Jan 29, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation - Markets Insider

Jan 29, 2025

When (KROS) Moves Investors should Listen - Stock Traders Daily

Jan 29, 2025

Jan 28, 2025

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation - Yahoo Finance

Jan 28, 2025

Jan 27, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation - Markets Insider

Jan 27, 2025

Jan 26, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - Markets Insider

Jan 26, 2025

Jan 25, 2025

KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jan 25, 2025

Assenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jan 25, 2025

Assenagon Asset Management S.A. Sells 158,767 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jan 25, 2025

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN

Jan 25, 2025

Jan 24, 2025

KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on ... - The Bakersfield Californian

Jan 24, 2025

Keros Therapeutics seals $200M deal with Takeda - MSN

Jan 24, 2025

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes - MSN

Jan 24, 2025

Jan 23, 2025

Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Neutral at Cantor Fitzgerald - Defense World

Jan 23, 2025

Jan 22, 2025

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS) - Business Wire

Jan 22, 2025

Keros Therapeutics seals $200M deal with Takeda By Investing.com - Investing.com Australia

Jan 22, 2025

Cantor Fitzgerald Estimates KROS FY2025 Earnings - MarketBeat

Jan 22, 2025

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - GlobeNewswire

Jan 22, 2025

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc.KROS - PR Newswire

Jan 21, 2025

Keros spikes as Teva deal takes effect; Cantor downgrades on trial setback - MSN

Jan 21, 2025